


Application No.: 09/716,778

Docket No.: 29473/11899

**IN THE CLAIMS:**

B1  
 1. (Currently Amended) A method of treating a wound in an animal or human comprising administering to said animal or human a pharmaceutical composition comprising a lipopeptide or lipoprotein with the following general structure:



wherein

$\text{R}^1$  and  $\text{R}^2$  stand for C<sub>7-25</sub>-alkyl, C<sub>7-25</sub>-alkenyl or C<sub>7-25</sub>-alkinyl,

X is S, O, or CH<sub>2</sub>,

$\text{Z}^1$  and  $\text{Z}^2$  stand for H or methyl,

W stands for CO or S(O)<sub>n</sub> (where n = 1 or 2) and

Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acid residues and the asymmetric carbon atom marked with \* has the absolute configuration S when X = S (sulfur).

2. (Currently Amended) The method of Claim 1, wherein Y comprises an amino acid sequence consisting of 1 to 25 amino acids.

3. (Currently Amended) The method of Claim 1, wherein Y comprises an amino acid sequence which is selected from the group consisting of:

- (i) amino acid sequence, which does not have an adverse influence on the water solubility of the lipopeptide or lipoprotein;
- (ii) GQTNT (SEQ ID NO:1);
- (iii) SKKKK (SEQ ID NO:2);

Application No.: 09/716,778

Docket No.: 29473/11899

Cont  
B1

(iv) GNNDESNISFKEK (SEQ ID NO:3);

(v) GQTDNNSQSQQPGSGTTNT (SEQ ID NO:4);

or a fragment or variant of the amino acid sequences in (ii), (iii), (iv) and (v) wherein said fragment or variant has macrophage stimulating activity.

4. (Currently Amended) The method of claim 1 wherein the C<sub>7-25</sub>-alkyl, C<sub>7-25</sub>-alkenyl, or C<sub>7-25</sub>-alkinyl is a C<sub>15</sub>-alkyl, C<sub>15</sub>-alkenyl or C<sub>15</sub>-alkinyl, respectively.

5. (Currently Amended) The method of claim 1 wherein the double bond(s) in the C<sub>7-25</sub>-alkenyl group has(have) the cis-configuration.

6. (Currently Amended) A method of treating a wound in an animal or human comprising administering to an animal or human a physiologically compatible lipopeptide or lipoprotein which carries at the N-terminal a dihydroxypropyl cysteine group with two, fatty acids bonded via ester bonds.

7. (Currently Amended) The method of claim 1 wherein said lipopeptide or lipoprotein [obtainable] is obtained from a mycoplasma clone.

8. (Currently Amended) The method of Claim 7, wherein said lipopeptide or lipoprotein is obtained from a *Mycoplasma fermentans* clone.

9. (Currently Amended) The method of claim 1 wherein said the lipopeptide or lipoprotein is water-soluble or amphoteric.

10. (Currently Amended) The method of claim 1 wherein said lipopeptide or lipoprotein selected from the group consists of:

(i) S-[2,3-bisphosphatidyl-oxy-(2RS)-propyl]cysteinyl-GQTNT (SEQ ID NO:5)

(ii) S-[2,3-bisphosphatidyl-oxy-(2RS)-propyl]cysteinyl-SKKKK (SEQ ID NO:6)

(iii) S-[2,3-bisphosphatidyl-oxy-(2RS)-propyl]cysteinyl-  
GNNDESNISFKEK (SEQ ID NO:7)

(iv) S-[2,3-bisphosphatidyl-oxy-(2S)-propyl]cysteinyl-  
GNNDESNISFKEK (SEQ ID NO:8) and

Application No.: 09/716,778

Docket No.: 29473/11899

(v) S-[2,3-bisphosphatidyl]cysteinyl-

GQTDNNSQSQQPGSGTTNT (SEQ ID NO:9)

11. (Currently Amended) The method of claim 1 wherein said lipopeptide or lipoprotein is in the form of a solution for epicutaneous application, an injection solution, a salve, a lotion, an aqueous suspension, a plaster impregnated or coated with said lipopeptide or lipoprotein, encapsulated in liposomes, or coupled to biodegradable carrier polymers.

12. (Currently Amended) The method of claim 1 wherein said wound is a wound after injury or surgical intervention, a chronically infected wound, a burn wound, a chronic, *Ulcus venosum*, or a wound of a patient who is corpulent or diabetic or are subjected to radiation or chemotherapy.

13. (New) The method of claim 1 wherein  $R^1$  and  $R^2$  are the same.

14. (New) The method of claim 1 wherein  $R^1$  and  $R^2$  are different.

15. (New) The method of claim where  $Z^1$  and  $Z^2$  are the same.

16. (New) The method of claim where  $Z^1$  and  $Z^2$  are different.

17. (New) The method of claim 6 wherein said fatty acids are long-chain fatty acids.

18. (New) The method of claim 6 wherein said fatty acids are the same.

19. (New) The method of claim 6 wherein said fatty acids are different.